Skip to main content
Premium Trial:

Request an Annual Quote

Syapse, Seoul National University Hospital Renew Precision Oncology Partnership

NEW YORK – Syapse, a maker of software to support precision oncology care, said today that it has extended its partnership with Seoul National University Hospital through a new, multiyear agreement. Length of the deal and financial terms were not disclosed.

San Francisco-based Syapse and the hospital said that they will "work toward building South Korea's first real-world data sharing network" for precision oncology. The partners envision that the network will serve other Asian countries as well. 

"Together we will work to build a precision medicine data sharing network in the region that will provide the high-quality real-world data and insights required to support hospitals in delivering the most informed personalized care to every cancer patient," Syapse CEO Ken Tarkoff said in a statement.  

Seoul National University Hospital and Syapse formed their partnership in January 2018. The health system agreed to install the Syapse data-aggregation platform in its 28 cancer centers across South Korea. Syapse entered into a deal then with cloud IT vendor Megazone to help the company reach other potential customers in Korea, Japan, and Vietnam.

In the last year and a half, Syapse and Seoul National University Hospital have been focusing on integrating and curating clinical, molecular, and outcomes data to scale up the capability to deliver precision cancer care, the partners said. 

The technology company and the hospital system also announced today that they would co-host a precision oncology symposium Nov. 22-23 in Seoul. East Asian Syapse customers, collectively known as the Syapse Precision Medicine Council Asia, will be invited to discuss best practices in establishing precision medicine programs and leveraging existing data sharing initiatives, among other topics.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.